Author | Alice Goodman


Minorities benefit from more sophisticated colon cancer screening

July 14, 2010

Current guidelines may be inadequate in at-risk African-American and Latino populations.

From the ONI archives: Ofatumumab turns in encouraging results in pretreated CLL

June 22, 2010

Standard therapy options are limited for patients with refractory chronic lymphocytic leukemia, with or without lymphadenopathy, and the results are generally poor. Ofatumumab (Arzerra), a novel human CD20 monoclonal antibody, could be the answer for improving outcomes in this patient population. Lead investigator William G. Wierda, MD, PhD, will share the final analysis of the results from this international study at ASH 2010.

Multigene assays influence treatment decisions in low-risk breast cancer patients

May 17, 2010

Tests carry a significant price tag, but reduction in chemotherapy use is potentially cost-saving.

Children with acute lymphoblastic leukemia gain little by participating in clinical trials

May 17, 2010

Parents and their children need to understand that advancing science does not always go hand-in-hand with a direct benefit to the patients.